STOCK TITAN

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

Rhea-AI Summary
Allergan Aesthetics (NYSE: ABBV) achieved record-breaking numbers during the fifth annual BOTOX® Cosmetic Day. November saw the highest number of BOTOX® Cosmetic treatments and gift card sales in history, with over 1.3 million website visitors. Additionally, more than 275,000 Allē members registered for the BOTOX® Cosmetic Day sweepstakes, and the company partnered with Snapchat to create an educational AR Lens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
-
Rhea-AI Summary
AbbVie (NYSE: ABBV) announces detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine during the prodrome phase. The Phase 3 study, PRODROME, showed that UBRELVY significantly reduced the likelihood of developing moderate or severe headache and reduced functional disability compared to placebo within 24 hours post-dose. This is a significant advancement in migraine treatment, providing an opportunity to avoid or attenuate the severity of the headache phase of a migraine attack.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary
Allergan Aesthetics (NYSE: ABBV) launches 'For Every BODY' campaign to showcase diverse stories and promote its Natrelle® breast implant portfolio. The campaign aims to highlight the importance of personal choice in breast surgery and features real women in various activities and fashion, emphasizing a customized look for every body.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, is celebrating the fifth annual BOTOX® Cosmetic Day on November 15. New and loyal members of Allē, the Allergan Aesthetics loyalty program, can enjoy exclusive offers throughout the month of November. These offers include a BOGO free gift card, double points on BOTOX® Cosmetic treatments, and a chance to win $25,000. BOTOX® Cosmetic is also partnering with Snapchat to create an interactive AR Lens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
Rhea-AI Summary
AbbVie reports third-quarter financial results, with diluted EPS of $1.00 on a GAAP basis and $2.95 on an adjusted basis. Net revenues decrease by 6.0% on a reported basis. Immunology portfolio revenues decrease by 11.3%, while neuroscience portfolio revenues increase by 22.1%. AbbVie raises its 2023 adjusted diluted EPS guidance range and announces a dividend increase for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
earnings
-
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, has announced positive results from two Phase 3 studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of glabellar lines. The studies showed that BoNT/E is a novel neurotoxin with a rapid onset of action and short duration of effect. If approved, BoNT/E will be the first of its kind available to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
clinical trial
Rhea-AI Summary
Allergan Aesthetics launches Reblossom, a coffee table book featuring patient stories and photographs of breast cancer survivors and thrivers. Proceeds from book sales benefit Living Beyond Breast Cancer. Allergan Aesthetics continues to support breast cancer patients through partnerships and initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
-
Rhea-AI Summary
AbbVie presents positive results from Phase 3 SEQUENCE study comparing risankizumab to ustekinumab for Crohn's disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
AbbVie's Phase 2b study of upadacitinib in adults with vitiligo shows positive results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
clinical trial
Rhea-AI Summary
AbbVie announces long-term efficacy and safety profile of RINVOQ® (upadacitinib) in treating atopic dermatitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
Abbvie Inc

NYSE:ABBV

ABBV Rankings

ABBV Stock Data

319.34B
1.76B
0.12%
71.89%
0.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.